Seno Medical Instruments Inc.

Seno Medical Instruments has designed, Imagio^®, an innovative new modality for improving the cancer diagnostic imaging process through the fusion of opto-acoustics with gray-scale ultrasound.

Seno owns the core patent on OA technology for any medical applications and has developed or in-licensed additional patents to enrich its portfolio. Together with the core patent, this constitutes a robust platform technology with a multitude of potential follow-on applications.

Diagnostic Imaging

Seno’s first clinical product targets breast cancer diagnosis and will be used as an adjunct to screening mammography, fusing opto-acoustics and ultrasound, providing clinicians new information to improve confidence in diagnosing malignant or benign masses. In the United States, the Imagio^® Breast Imaging System (9100) has FDA PMA approval. In Europe, the current Model 9100 is pending CE mark under MDR.

Future Applications

While the commercialization of Seno’s Imagio^® Breast Imaging System is underway today, many other exciting applications lie in the future. These could include research, screening, diagnostic and treatment devices for other forms of cancer including thyroid, head and neck, prostate, cervical, ovarian and bladder, in addition to therapeutic monitoring of drugs.